ChoA Pharmaceutical Co., Ltd.

As of March 31, 2026, ChoA Pharmaceutical Co., Ltd. carries a market capitalization of 137.24B, placing it among publicly traded companies globally. Its enterprise value stands at 158.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, ChoA Pharmaceutical Co., Ltd. has 30.98M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 1.84, and the price-to-book ratio stands at 5.48.

These figures are as of March 31, 2026. The EV/Sales ratio of 2.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 158.36B versus a market cap of 137.24B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, ChoA Pharmaceutical Co., Ltd. maintains a current ratio of 1.08, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 127.48, indicating elevated leverage, while an interest coverage ratio of -2.62 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, ChoA Pharmaceutical Co., Ltd. posted a negative return on equity (ROE) of -17.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.25, reflecting losses generated across the asset base. The company generates approximately 228.43M in revenue per employee across its workforce of 261.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.10 indicates how many times ChoA Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, ChoA Pharmaceutical Co., Ltd. recorded 939.65M in income tax expense. The company reported a pretax loss of -4.37B and -4.73B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, ChoA Pharmaceutical Co., Ltd.'s stock has declined approximately 66.13% over the past 52 weeks. The 50-day moving average sits at 2,694.02, while the 200-day moving average is 3,910.46.

Over the twelve months ended March 31, 2026, ChoA Pharmaceutical Co., Ltd. generated 59.62B in revenue and converted that into -4.73B in net income, yielding earnings per share of -214.23. EBITDA reached -3.20B, while operating income came in at -5.61B.

As of March 31, 2026, ChoA Pharmaceutical Co., Ltd. holds 3.02B in cash and equivalents against 27.56B in total debt, resulting in a net debt position of 22.14B. Total book value stands at 25.03B, with working capital of 2.76B providing operational flexibility.

ChoA Pharmaceutical Co., Ltd. produced -3.52B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.16B in capital expenditures, free cash flow totaled -4.67B - equivalent to -188.56 per share.

Over the twelve months ended March 31, 2026, ChoA Pharmaceutical Co., Ltd. posted a gross margin of 36.55, reflecting its pricing power and cost economics. The operating margin of -9.41 and net profit margin of -7.93 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -4.26: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.51, meaning ChoA Pharmaceutical Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ChoA Pharmaceutical Co., Ltd.'s most recent stock split took place on August 27, 2026 with a 5:1 split ratio.

As of March 31, 2026, ChoA Pharmaceutical Co., Ltd. has an Altman Z-Score of 1.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.